9
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Phenylalkynes to treat histamine mediated conditions

Pages 1759-1762 | Published online: 02 Mar 2005

Bibliography

  • ARRANGJM, GARBURG M, SCHWARTZ JC: Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302:832–837.
  • SCHLICKER E, BETZ R, GOTHERT M: Histamine H3 receptor-mediated inhibition of release in the rat brain cortex. Naunyn SchrinedebergS Arch. Pharmacol. (1988) 337:588–590.
  • SCHLICKER E, FINK K HINTERTHANER M, GOTHERT M: Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedeberis Arch. Pharmacol. (1989) 340:633–638.
  • SCHLICKER E, FINK K, DETZNER M, GOTHERT M: Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. I Neural Transmission (1993) 93:1–10.
  • LEURS R, SMIT MJ, TIMMERMAN H: Molecular pharmacological aspects of histamine receptors. Pharmacol Thec (1995) 66:413–363.
  • LOVENBERG TW, POLAND B, WILSON S et al: Cloning and functional expression of the human H3 receptor. MM. Pharmacol. (1999) 55:1101–1107.
  • WELLENDORPF P, GOODMAN MW,BURSTEIN WS, NASH NR, BRANN MR, WEINER DM: Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neurophannacology (2002) 42:929–940.
  • •Paper that suggests that there is yet another level of complexity to the histamine story. See also: LEURS R, WATANABE T, TIMMERMAN H: Histamine receptors are finally 'coming out'. Trends Pharmacol. Sci (2001) 22:337–339.
  • ODA T, MORIKAWA N, SAITO Y, MASUHO Y, MATSUMOTO S: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. Biol. Chem. (2000) 275:36781–36786.
  • LEURS R, BLANDINA P, TEDFORD C,TIMMERMAN H: Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol. Sci. (1998) 19:177–183.
  • ROULEAU A, GARBARG X, LIGNEAU C et al.: Bioavailability, antinociceptive and antiinflammatory properties of BP 2–94, a histamine H3 receptor agonist prodrug. .1. Pharmacol. Exp. Then (1997) 281:1085–1094.
  • HASHIMOTO T, HARUSAWA S, ARAKI L et al.: A selective human H4-receptor agonist: ( ) 2 cyano 1 methy1-3-{(2R,5/0-541H- imidazol-4 (5)tetrahydrofuran- 2-Amethylguanidine. Med. Chem. (2003) 46:3162–3165.
  • GANELLIN CR, LEURQUIN F, PIRIPITSI A et al.: Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch. Pharm. Phann. Med. Chem. (1998) 331:395–404.
  • FOROOZESH M, PRIMROSE G, GUO Z, BELL LC, ALWORTH WL, GUENGERICH FP: Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem. Res. Toxicol. (1997) 10:91–102.
  • FAGHIH R, BENNANI Y, BLACK LA et al.: Histamine H3 receptor antagonists: from high throughput screening (HTS) to drug-like molecules. Abstracts of Papers, 226th ACS National Meeting. New York, USA (2003) MEDI054.
  • HALLI WELL WH: Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. (1997) 2553–61.
  • •An excellent review of the phospholipidosis issue and its importance in drug development
  • REASOR M, KACEW S: Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. (2001) 226:825–830.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.